Apexigen Stock Price, News & Analysis (NASDAQ:APGNW) Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.02▼$0.0350-Day Range$0.02▼$0.0552-Week Range$0.01▼$0.37Volume3,100 shsAverage Volume17,375 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisHeadlinesShort InterestSocial MediaStock AnalysisHeadlinesShort InterestSocial Media About Apexigen Stock (NASDAQ:APGNW)Apexigen Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody therapeutics for oncology. It develops a pipeline of product candidates, including APX005M, a humanized agonist antibody that is in Phase II clinical development for the treatment of solid tumors, such as melanoma, esophageal and gastroesophageal junction, sarcoma, and rectal and ovarian cancers in combination with immunotherapy, chemotherapy, radiation therapy, and cancer vaccines; and APX601, a humanized antagonist antibody that is in Phase I/II clinical trial for the treatment of multiple tumor indications, as well as APX801, an NK cell engager to activate natural killer cells to killing of tumor cells. The company was founded in 2010 and is based in San Carlos, California.Read More APGNW Stock News HeadlinesAugust 11, 2023 | businesswire.comAPEXIGEN INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apexigen, Inc ...June 3, 2023 | benzinga.comLifshitz Law PLLC Announces Investigations of APGN, GNL, RTL, and BACKNovember 28, 2023 | RYSE INC. (Ad)Secure your stake in the Smart Home industry.Last chance to invest in RYSE – the shade automation technology launching in over 100 Best Buy stores this month.May 27, 2023 | benzinga.comApexigen Stock (NASDAQ:APGN), Insider Trading ActivityMay 25, 2023 | msn.comApexigen (APGN) to Get Acquired by Pyxis Oncology, Stock UpMay 25, 2023 | msn.comEF Hutton Downgrades Apexigen (APGN)May 24, 2023 | theglobeandmail.comBiotech Soars On Acquisition AnnouncementMay 24, 2023 | msn.comSmall SPAC Biotech Apexigen To Be Acquired Pyxis Oncology For $16MNovember 28, 2023 | RYSE INC. (Ad)Secure your stake in the Smart Home industry.Last chance to invest in RYSE – the shade automation technology launching in over 100 Best Buy stores this month.May 24, 2023 | investorplace.comWhy Is Apexigen (APGN) Stock Up 31% Today?May 24, 2023 | msn.comUS Futures Lower as Investors Eye Debt Ceiling Talks, Await Fed Minutes ReleaseMay 24, 2023 | finance.yahoo.comPyxis Oncology to Acquire ApexigenMay 24, 2023 | msn.comApexigen surges ~40% on all-stock acquisition by Pyxis OncologyMay 24, 2023 | technews.tmcnet.comAPGN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Apexigen, Inc. Is Fair to ShareholdersFebruary 27, 2023 | bizjournals.comMonths after going public, Peninsula biotech cuts staff, weights its options for futureFebruary 27, 2023 | bizjournals.comMonths after going public, Peninsula biotech Apexigen cuts staff, weighs its options for futureSee More Headlines Receive APGNW Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Apexigen and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:APGNW CUSIPN/A CIK1814140 Webwww.apexigen.com Phone650-931-6236FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Xiaodong Yang M.D. (Age 62)Ph.D., Pres, CEO & Director Comp: $541.33kMs. Amy Wong (Age 56)Sr. VP of Fin. & Operations Comp: $368.92kDr. Frank J. Hsu M.D. (Age 61)Chief Medical Officer Comp: $212.19kMr. William E. Duke Jr. (Age 50)Chief Financial Officer Mr. Francis W. Sarena (Age 51)Chief Operating Officer Dr. Jason Wright Ph.D.Sr. VP of CMCMore ExecutivesKey Competitors60 Degrees PharmaceuticalsNASDAQ:SXTPWAinosNASDAQ:AIMDWAlpha Tau MedicalNASDAQ:DRTSWApollomicsNASDAQ:APLMWCardio DiagnosticsNASDAQ:CDIOWView All Competitors APGNW Stock Analysis - Frequently Asked Questions Who are Apexigen's major shareholders? Apexigen's stock is owned by many different institutional and retail investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%). This page (NASDAQ:APGNW) was last updated on 11/28/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apexigen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.